Norwegian commercial salmon genetics company providing selective breeding programmes and genomic expertise for European aquaculture research consortia.
Benchmark Genetics Norway AS is a private aquaculture genetics company based in Bergen, operating under the salmobreed.no brand — one of Norway's leading salmon selective breeding programmes. Their core work is designing and delivering genetically superior broodstock to fish farmers, using genomic selection tools to improve traits such as growth rate, disease resistance, feed conversion, and product quality across Atlantic salmon and other farmed species. In EU research projects, they contribute industry-side expertise: real-world breeding data, commercial production system knowledge, and a direct channel to apply genomic and nutritional innovations at commercial scale. They sit at the intersection of applied genetics, aquaculture operations, and digital farm management.
Both FutureEUAqua and AquaIMPACT centre on genetic improvement of farmed fish, with AquaIMPACT explicitly targeting genomic innovations for Atlantic salmon, rainbow trout, gilthead seabream, and European seabass.
FutureEUAqua (€352,656) addressed climate-resilient organic and conventional European aquaculture, covering welfare, feeding, packaging, and IoT-enabled production monitoring.
AquaIMPACT combined genomic and nutritional innovations to improve feed efficiency in farmed fish, reflecting BGN's industry role in translating research into commercial feeding programmes.
FutureEUAqua included IoT and smart-software as listed keywords, indicating early-stage engagement with digital farm monitoring as a complement to biological expertise.
In their first H2020 engagement (FutureEUAqua, 2018), BGN operated across a broad sustainable aquaculture agenda — covering production systems, IoT, welfare, feeding, socioeconomy, and packaging — essentially contributing to a wide-scope platform project. By 2019 (AquaIMPACT), their involvement narrowed to a sharper, more technically specific focus: genomics, fish nutrition, and the commercial development of genetically superior broodstock across multiple Mediterranean and Atlantic species. The shift is a classic industry partner arc: from general sector participation toward targeted genetic and molecular tools where their proprietary breeding data and commercial operations add the most value.
BGN is moving deeper into precision genomics and multi-species breeding, positioning itself as an industry anchor for consortia that need validated commercial broodstock data alongside academic genomic research.
BGN participates exclusively as a consortium partner — they have never led an H2020 project — which reflects their role as an industry knowledge-holder rather than a research coordinator. Despite a small project footprint (2 projects), they have accumulated 53 unique consortium partners across 15 countries, suggesting they join large, multi-partner Innovation Actions where their commercial breeding data and salmon industry access are the primary contribution. This makes them a high-value but selective collaborator: they bring real-world fish farm access and proprietary genetic databases that few academic partners can replicate.
BGN has worked with 53 distinct partners across 15 countries despite only two projects, indicating they joined broad European aquaculture consortia with wide geographic spread. Their network likely spans Nordic aquaculture nations (Norway, Scotland, Denmark), Southern European sea bass and sea bream producers (Greece, Spain, Italy), and leading marine research institutes.
BGN is one of very few private genetics companies in Norway with direct H2020 project experience — most European aquaculture genetics IP sits inside large breeding companies that rarely open their data to research consortia. Their participation under the salmobreed.no brand gives them credibility with both Norwegian salmon producers and Southern European sea bream/sea bass farmers, making them unusually useful for pan-European multi-species aquaculture projects. For a consortium that needs commercial validation of genomic tools in live breeding programmes, BGN offers something most universities cannot: access to operational selective breeding pipelines at commercial scale.
